• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bexson Biomedical aims to extend its wearable drug delivery device to psychoactive drugs

August 11, 2021 By Sean Whooley

Bexson Biomedical Ketamine Pump
Bexson is developing a wearable infusion pump with Stevanato Group. (Image from Bexson)

Bexson Biomedical announced today that it launched an R&D initiative to develop subcutaneous formulations of psychoactive therapeutics.

Santa Barbara, Calif.-based Bexson’s effort will apply its existing subcutaneous formulation technology to build several psychoactive drug scaffolds for treating mental health indications, including post-traumatic stress disorder (PTSD) and depression.

Formulations developed through the R&D initiative are designed for controlled delivery through Bexson’s proprietary wearable subcutaneous infusion pump technology in development with Stevanato Group. The company recently earned a U.S. patent for its BB106 ketamine therapy through the proprietary delivery platform.

“As we developed our BB106 subcutaneous ketamine therapy we realized two things,” Bexson co-founder & CSO Dr. Jeffrey Becker said in a news release. “First, the wearable patch pump we are developing with Stevanato Group is the ideal platform for controlled release of a controlled substance. Two, Bexson’s patented formulation technology could be applied to a vast number of psychedelic and empathogen compounds to improve experience and accessibility, while providing increased safety and dosing precision.

“As our research has progressed, we have been pleased to find both our formulation and pump technology are highly modular.”

Bexson said it has initiated formulation development and stability work on several compounds that represent high-impact targets for treating mental health, addiction and pain disorders. Compounds such as DMT and mescaline are being formulated for subcutaneous administration.

Late last year, the company filed five provisional patents to apply its new delivery and formulation technology to a number of compounds and broad scaffolds with the potential to become new mental health treatments, including tryptamines, phenylethylamines, lysergamides, aminoindanes, benzofurans, arylcyclohexylamines, and cathinones.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Research & Development Tagged With: Bexson Biomedical

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS